Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Reducing Disparities in the Quality of Advance Care Planning for Older Adults (EQUALACP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03516994
Recruitment Status : Enrolling by invitation
First Posted : May 7, 2018
Last Update Posted : September 10, 2019
Sponsor:
Information provided by (Responsible Party):
Duke University

Tracking Information
First Submitted Date  ICMJE April 30, 2018
First Posted Date  ICMJE May 7, 2018
Last Update Posted Date September 10, 2019
Actual Study Start Date  ICMJE January 16, 2019
Estimated Primary Completion Date September 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 30, 2018)
  • Proportion of African Americans who complete advance care planning [ Time Frame: 12 months ]
    completion of an advance care planning document (living will, healthcare proxy, medical orders, Five Wishes, other); discussion with clinician documented in chart, patient report of advance care planning discussion (designated decision-maker, discussed values, goals, preferences) with family, friends, or others
  • Proportion of Whites who complete advance care planning [ Time Frame: 12 months ]
    completion of an advance care planning document (living will, healthcare proxy, medical orders, Five Wishes, other); discussion with clinician documented in chart, patient report of advance care planning discussion (designated decision-maker, discussed values, goals, preferences) with family, friends, or others
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 30, 2018)
  • Difference in Proportion of Whites versus African Americans who complete advance care planning [ Time Frame: 12 months ]
    Difference of proportion in whites versus African Americans who complete formal or informal advance care planning
  • Patient Readiness to Engage in Advance Care Planning [ Time Frame: 3 months ]
    Measure assessing patient's readiness to name decision-maker, discuss care preferences, complete legal advance directive
  • Patient Quality of Life [ Time Frame: 3 months, 6 months, one year ]
    Measure (Promis 29) assessing quality of life, including domains of physical functional, emotional, and social well-being
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Reducing Disparities in the Quality of Advance Care Planning for Older Adults
Official Title  ICMJE REducing Disparities in the QUALity of Palliative Care for Older African Americans Through Improved Advance Care Planning (EQUAL ACP)
Brief Summary This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community. The two approaches are a structured approach with an advance care planning conversation led by a trained person using Respecting Choices (First Steps) and a patient-driven approach which includes a Five Wishes advance care planning form written in plain language. The study will determine which approach is more effective at increasing advance care planning within each racial group and reducing differences between the two groups in advance care planning.
Detailed Description

Advance care planning (ACP) involves patients making decisions about the kind of medical care they would want to receive if they became unable to speak for themselves. Patients share their wishes in a written document (living will or healthcare proxy) and/or discuss their wishes with family, friends, and doctors. ACP improves the quality of end-of-life care by increasing the likelihood that patients receive care that reflects their preferences and values. Seriously ill African Americans are less likely to take part in advance care planning and experience lower quality care at the end of life, including poorer communication with clinicians and a lower likelihood of receiving the kind of care that they would want.

This study will include 800 seriously or chronically ill community-dwelling older adults (equal number of African Americans and whites) and their caregivers from 10 primary care practices at five medical centers in the Deep South. Eligible patients include those with cancer, advanced heart disease, advanced lung disease, end-stage kidney disease, cirrhosis, diabetes with severe complications, recurrent hospitalizations, or difficulty with basic activities of daily living. For each enrolled patient, one caregiver who is likely to assist the patient with healthcare decisions is also eligible to participate.

The goals of the study are to:

  • Compare the effectiveness of two approaches to increasing formal advance care planning (completing written documents like living wills, health care proxies, medical orders for life-sustaining treatments, or other advance directives) and informal advance care planning (having conversations with doctors, family, friends, and others about wishes for future healthcare) for African Americans and for Whites.
  • Determine which intervention is most effective in reducing differences between African Americans and Whites in rates of advance care planning.
  • Determine whether the effectiveness of the advance care planning approach differs based on whether the person assisting with advance care planning is of the same or different race as the patient.

Administered by community health workers, the two advance care planning approaches which will be compared are:

  • Patient-driven approach which includes a Five Wishes Form (advance directive written in easy to understand language)
  • Structured approach with an advance care planning conversation led by a trained person using Respecting Choices (First Step) conversation guide.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Mixed-methods, longitudinal, multi-site study, cluster randomized trial
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE
  • Metastatic Cancer
  • Congestive Heart Failure
  • Chronic Obstructive Pulmonary Disease
  • Parkinson Disease
  • Interstitial Lung Disease
  • Amyotrophic Lateral Sclerosis
  • End Stage Liver Disease
  • End Stage Renal Disease
  • Diabetes Complications
Intervention  ICMJE
  • Behavioral: Respecting Choices First Steps
    Advance Care Planning Approach
  • Behavioral: Five Wishes Form
    Advance Care Planning Approach
Study Arms  ICMJE
  • Experimental: Structured Advance Care Planning
    In the structured advance care planning approach, patients will participate in a 60 to 90 minute facilitated advance care planning conversation with a trained person using Respecting Choices (First Steps) guide and will receive a state advance directive form. The advance care planning facilitator will follow-up as needed after the session to answer additional questions.
    Intervention: Behavioral: Respecting Choices First Steps
  • Active Comparator: Patient Driven Advance Care Planning
    In the patient-driven advance care planning approach, patients receive a Five Wishes Form (easy to understand advance directive written in plain language), a state advance directive form, and at least two follow-up phone calls with an advance care planning contact who will answer questions.
    Intervention: Behavioral: Five Wishes Form
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Enrolling by invitation
Estimated Enrollment  ICMJE
 (submitted: April 30, 2018)
800
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 1, 2022
Estimated Primary Completion Date September 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria for Patients:

  • African-American or White
  • age 65 or greater
  • English-speaking
  • residing in non-institutional setting
  • cognitively able to participate in advance care planning
  • Serious or chronic illness including: metastatic cancer; end stage renal disease; advanced liver disease, heart disease or lung disease; amyotrophic lateral sclerosis, severe Parkinson's disease; 2 or more unplanned hospitalizations in the last year; requiring assistance with any basic activity of daily living
  • Serious illness based on the following: Clinician answers "no" to the surprise question: "Would you be surprised if this person died in the next 12 months?"

Exclusion Criteria for Patients:

  • residence in nursing home or assisted living facility
  • diagnosis of dementia or unable to consent
  • documented advance care plan (living will, health care proxy, MOST form, provider note)
  • current or prior use of hospice
  • current or prior use of non-hospice palliative care except inpatient palliative care consultation
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 65 Years and older   (Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03516994
Other Study ID Numbers  ICMJE Pro00091633
OLC-1609-36381 ( Other Grant/Funding Number: Patient-Centered Outcomes Research Institute )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Duke University
Study Sponsor  ICMJE Duke University
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Kimberly Johnson, MD Duke University
PRS Account Duke University
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP